Bristol-Myers Squibb, seeking to re-energize its cancer pipeline, is turning to an artificial intelligence startup for help, inking a deal to use the firm’s analytical tools and “real-world” patient data to better target and accelerate clinical trials.
Trending:
Bristol-Myers Squibb turns to an AI startup to accelerate cancer research